In neoadjuvant chemotherapy (NAC) setting, a previous pooled analysis of four neoadjuvant chemotherapy clinical trials (GeparSepto, GeparOcto, GeparX, and Gain-2 neoadjuvant) confirmed that HER2-low breast cancer had a significantly lower pathological complete response(pCR) rate than HER2-zero patients (24). Here, ERBB2 is linked to breast carcinoma.